Centanafadine Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Centanafadine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Centanafadine Hydrochloride can convert its Small molecule drug profile and DAT x NET x SERT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Centanafadine Hydrochloride (query alias: Centanafadine Hydrochloride) |
|---|---|
| Modality / target | Small molecule drug; DAT x NET x SERT; Dopamine reuptake inhibitors, NET inhibitors, Serotonin reuptake inhibitors |
| Highest global status | NDA/BLA |
| Originator | Euthymics Bioscience, Inc. |
| Active developers | Otsuka Pharmaceutical Development & Commercialization, Inc., Kanae Co., Ltd., Otsuka Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Attention Deficit Disorder With Hyperactivity, Generalized anxiety disorder, Depressive Disorder, Major. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07253441 | Phase 1 | Completed | 174 | Cohorts 1, 2, 3, and 4: Maximum Plasma Concentration (Cmax) of CTN |
| NCT07465731 | Phase 1 | Completed | 62 | Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t (AUCt) of Centanafadine |
| NCT07486895 | Phase 1 | Completed | 44 | Maximum Plasma Concentration (Cmax) of Centanafadine |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets After Oral Administration in Adult Subjects With Binge Eating Disorder
Phase 2; n=147; evaluation: not stated. Reported fields: Change From Baseline in Number of Binge Eating Days Per Week(Least Squares Mean) = -3.01 binge eating days per week (Standard Error, 0.23); Change From Baseline in Number of Binge Eating Days Per Week(Least Squares Mean) = -3.07 binge eating days per week (Standard Error, 0.23); Change From Baseline in Number of Binge Eating Days Per Week(Least Squares Mean): Treatment Difference = -0.42(95% CI, -1.06 to 0.21), P-Value = 0.1893; Treatment Difference = -0.06(95% CI, -0.69 to 0.57), P-Value = 0.8502
Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial
Phase 3; n=459; evaluation: Positive. Reported fields: Adverse Event: aggression = 1 event in 164.4 mg group ; Adverse Event: aggression = 1 event in 164.4 mg group ; Adverse Event: aggression = 1 event in 164.4 mg group
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
Phase 2; n=50; evaluation: not stated. Reported fields: Percentage of Participants With a Continuous Smoking Abstinence Rate = 0 percentage of participants (90% Confidence Interval, 0.0 - 5.9); -; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Centanafadine Hydrochloride addresses Attention Deficit Disorder With Hyperactivity, Generalized anxiety disorder, Depressive Disorder, Major. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 56 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DAT x NET x SERT records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-30 | Azurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets | Approved | Financial terms not disclosed |
| 2026-03-27 | Otsuka completes USD 1.2b acquisition of Transcend Therapeutics for PTSD neuroplastogen | Phase 3 | US$700.0M upfront; US$525.0M milestones; US$1,225.0M stated total |
| 2026-03-19 | Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics | Approved | US$650.0M upfront; US$135.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
